Endonovo Therapeutics, Inc. (ENDV)

0.0027 -0.0001 (-4.59%) As of 10:06AM EDT. Market open.

Endonovo Therapeutics, Inc.

6320 Canoga Avenue
15th Floor
Woodland Hills, CA 91367
United States
800 489 4774
https://www.endonovo.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Alan Brian Collier	Chairman & CEO	300k	N/A	1966
Mr. Don Calabria	Vice President of Operations	N/A	N/A	N/A
Mr. Garry Michael Kann	Head of Corporate Development	N/A	N/A	N/A
Mr. Ira Weisberg	President & Chief Commercial Officer of Medical Division	N/A	N/A	1949

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

Corporate governance

Endonovo Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.